- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.10. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | 2.783 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| 02.10. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.09. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth | 302 | ACCESS Newswire | Chief Business Officer, Dylan Wenke, Participates in Virtual Investor "What This Means" SegmentAccess the segment here HOUSTON, TX / ACCESS Newswire / September 1, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)... ► Artikel lesen | |
| 27.08. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference | 470 | ACCESS Newswire | Video webcast now available here HOUSTON, TX / ACCESS Newswire / August 27, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline... ► Artikel lesen | |
| 12.08. | CNS Pharmaceuticals GAAP EPS of -$0.37 misses by $0.13 | 6 | Seeking Alpha | ||
| 12.08. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation | 606 | ACCESS Newswire | Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline... ► Artikel lesen | |
| CNS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 12.08. | CNS Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 02.07. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 08.06. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment | 390 | ACCESS Newswire | Access the segment here HOUSTON, TX / ACCESS Newswire / June 8, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative... ► Artikel lesen | |
| 20.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress | 477 | ACCESS Newswire | Access the CEO Connect segment here HOUSTON, TX / ACCESS Newswire / May 20, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline... ► Artikel lesen | |
| 14.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress | 373 | ACCESS Newswire | Oversubscribed $22.5 million financing anticipated to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with... ► Artikel lesen | |
| 04.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing | 653 | ACCESS Newswire | The private placement includes participation from several leading healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare PartnersProceeds expected to... ► Artikel lesen | |
| 11.03. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline | 679 | ACCESS Newswire | Newly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, two of biopharma's largest and fastest-growing marketsStrategic transformation... ► Artikel lesen | |
| 02.03. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team | 414 | ACCESS Newswire | Dr. Kelley adds two decades of highly relevant drug development and regulatory strategy experience spanning oncology, rare diseases and CNSNewly formed executive team is committed to execution and company... ► Artikel lesen | |
| 17.02. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation | 676 | ACCESS Newswire | New Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optimization and Transactional Expertise to Support Company Growth and Value Creation HOUSTON, TX / ACCESS... ► Artikel lesen | |
| 27.01. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Issues Letter to Shareholders | 414 | ACCESS Newswire | Newly Appointed President & Chief Executive Officer, Rami Levin, Discusses Plans for a New Era at CNS PharmaceuticalsStrategic Focus, Pipeline Optimization and Formalizing Roadmap for Near and Long-Term... ► Artikel lesen | |
| 17.12.25 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces CEO Transition | 506 | ACCESS Newswire | Industry veteran Rami Levin, MBA appointed as President & Chief Executive Officer HOUSTON, TX / ACCESS Newswire / December 17, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company")... ► Artikel lesen | |
| 17.11.25 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 504 | ACCESS Newswire | Cash expected to fund operations into the second half of 2026Company focused on advancing next-generation anti-cancer therapies derived from well-established drug classes, now engineered to cross the... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 3,000 | +0,33 % | PTA-News: Biofrontera AG: Biofrontera unterzeichnet Vertriebsvereinbarung mit Propaira Pty Ltd für Ameluz in Australien | DJ PTA-News: Biofrontera AG: Biofrontera unterzeichnet Vertriebsvereinbarung mit Propaira Pty Ltd für Ameluz in Australien
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: Biofrontera... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,161 | -10,35 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights | VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) granted accelerated approval by U.S. Food and Drug Administration (FDA) to reduce the frequency of surgery in adults with Recurrent... ► Artikel lesen | |
| CLINUVEL | 4,524 | -1,09 % | CLINUVEL PHARMACEUTICALS LIMITED: Results of Meeting | ||
| INFLARX | 1,205 | +10,65 % | InflaRx: 2027 - warum die nächsten Studien jetzt zählen | ||
| INTELLIA THERAPEUTICS | 10,200 | +1,80 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DEFENCE THERAPEUTICS | 0,191 | -9,29 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Convertible Debenture Interest Payment | Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| EDITAS MEDICINE | 2,340 | +4,00 % | Editas auf der Guggenheim Healthcare Innovation Conference: Strategischer Fokus auf In-vivo-CRISPR | ||
| BIOCRYST PHARMACEUTICALS | 6,894 | +2,25 % | BioCryst Pharmaceuticals (NDQ:BCRX): The Market Is Valuing ORLADEYO, But Is Navenibart The Real Prize? | ||
| CARDIOL THERAPEUTICS | 0,923 | +0,98 % | Milliardenchance Herztherapie: Cardiol Therapeutics, Kiniksa und Novo Nordisk | Erstellt und veröffentlicht im Auftrag von Cardiol Therapeutics Die Behandlung von entzündlichen Herzerkrankungen entwickelt sich aktuell zu einem der lukrativsten Segmente der Pharmabranche. Das bislang... ► Artikel lesen | |
| GERON | 0,885 | +1,80 % | Geron auf der Stifel Healthcare Conference 2026: RYTELO gewinnt an Dynamik | ||
| IBIO | 0,688 | -1,64 % | iBio, Inc.: iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update | ||
| IMMUNITYBIO | 6,140 | +1,49 % | ImmunityBio, Inc.: ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026 | Senior leadership will discuss ImmunityBio's clinical and commercial priorities at Jefferies Global Healthcare Conference and UBS Global Biopharma Conference in London
ImmunityBio, Inc. (NASDAQ:... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,370 | -1,75 % | Arbutus Biopharma GAAP EPS of $0.30 beats by $0.32, revenue of $0.3M misses by $0.7M | ||
| IMMATICS | 5,840 | +1,74 % | Immatics Announces Third Quarter 2026 Financial Results and Business Update | Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) is on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 1,230 | 0,00 % | Cellectar Biosciences GAAP EPS of -$0.46 beats by $0.10 |
CNS PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,970 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CNS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.